Neurogene Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On February 14, 2022, Neoleukin Therapeutics, Inc. (the “Company”) received notice from Robert Ho of his intention to resign as the Company’s Chief Financial Officer and Corporate Secretary to pursue another opportunity, effective March 1, 2022.
Extracted from this filing and checked against the source text.
Robert Ho departed as Chief Financial Officer and Corporate Secretary at Neurogene Inc..
On February 14, 2022, Neoleukin Therapeutics, Inc. (the “Company”) received notice from Robert Ho of his intention to resign as the Company’s Chief Financial Officer and Corporate Secretary to pursue another opportunity, effective March 1, 2022.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.